With an increasing prevalence during the past decades, atopic dermatitis has become a
global health issue. A literature search following a targeted approach was undertaken to …

Atopic dermatitis (AD) is a prevalent inflammatory skin disorder affecting all age and ethnic
groups. The age-dependent varying appearance and extent of pruritic lesions are …

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease with a life-time
prevalence of 10–20% in western countries. Patients suffer from stigmatizing eczematous …

Introduction Atopic dermatitis (AD) is a difficult-to-treat inflammatory skin disease with a high
impact on patients' quality of life. Dupilumab, an IL-4 and IL-13 inhibitor, was the first …

Background Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-
4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in …

The last decade has seen an unprecedented pace of change, particularly of clinical
research in atopic dermatitis (AD). This review summarizes some key discoveries. Over the …

Background Data from early-stage studies suggested that interleukin (IL)-4 and IL-13 are
requisite drivers of atopic dermatitis, evidenced by marked improvement after treatment with …

Background Clinical trial data for dupilumab, a monoclonal antibody against the interleukin‐
4 receptor (IL‐4Rα), have shown that it is safe and effective for the treatment of moderate to …

Atopic dermatitis (AD), also known as atopic eczema, is a chronic inflammatory skin
condition associated with a significant health-related and socioeconomic burden, and is …

Atopic dermatitis (AD) is a multifaceted disease that involves a complex interplay between
the skin and the immune system. The course of the disease depends strongly on the genetic …